This is a product review of the use of Olaparib in the maintenance treatment of advanced ovarian cancer. This review discusses the evidence in support of the use of Olaparib, its pharmacology including its mechanism of action, and efficacy and tolerability demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Linda Mileshkin, Deputy Director of Medical Oncology at the Peter MacCallum Cancer Centre, and clinical trials lead for Gynae-Oncology in the Parkville Cancer Clinical Trials Unit.
Please login below to download this issue (PDF)